Biotech firm iBio (NYSEA:IBIO) has incorporated EngageTx, a machine learning-driven technology, into its development roadmap. This T-cell engaging antibody panel assists in generating bispecific antibodies targeting cancer cells. In particular, the firm is developing a novel Trophoblast Cell Surface Antigen 2 (TROP-2) bispecific molecule to target TROP-2-positive cancers. In addition to their focus on oncology,…